Activity of 3-NAntC (peptide 3) in breast cancer cell lines compared to benign cells. Tumor (MDA-MB-231 and MCF-7) and benign (HDFa, HMEC, and MCF10A) cell lines were treated with 3-NAntC for 24, 48, and 72 h at the concentration range of 0.2–1.0 µg/mL. Cellular viability assay was conducted using the MTT method. Data are shown as mean ± SEM of at least three independent assays in triplicate. (a–c) Benign cell lines treated with the same concentrations of 3-NAntC were compared to the control (0 µg/mL) using two-way ANOVA and a Bonferroni post hoc test. (d–f) MDA-MB-231 and MCF-7 tumor cell lines were treated with various concentrations of 3-NAntC and compared to the HMEC benign cell line using two-way ANOVA and a Bonferroni post hoc test, # p < 0.05, and #### p < 0.0001.
|